QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 morgan-stanley-maintains-overweight-on-biontech-lowers-price-target-to-131

Morgan Stanley analyst Terence Flynn maintains BioNTech (NASDAQ:BNTX) with a Overweight and lowers the price target from $13...

Core News & Articles

https://www.nature.com/articles/d41586-025-03093-6

 jp-morgan-maintains-neutral-on-biontech-raises-price-target-to-121

JP Morgan analyst Jessica Fye maintains BioNTech (NASDAQ:BNTX) with a Neutral and raises the price target from $116 to $121.

Core News & Articles

- Reuters 

Core News & Articles

- Reuters

 moderna-reports-8-fold-jump-in-antibodies-with-updated-spikevax

Moderna's updated Spikevax shows strong antibody response and safety, targeting dominant COVID-19 variants like LP.8.1 in h...

 synopsys-chewy-and-the-trade-desk-are-among-top-10-large-cap-losers-last-week-sep-8--sep-12-are-the-others-in-your-portfolio

Earnings misses, weak guidance, and downgrades drove large-cap decliners—led by Synopsys, Chewy, and The Trade Desk—while biote...

 pfizer-moderna-biontech-stocks-tumble-after-report-of-plan-to-link-covid-vaccines-to-child-deaths

Shares of COVID-19 vaccine makers are trading lower Friday. Vaccine stocks fell Friday on a Washington Post report that Trump a...

Core News & Articles

- Reuters

Core News & Articles

https://www.washingtonpost.com/health/2025/09/12/covid-vaccine-child-death-cdc/

 pfizer-biontech-roll-out-covid-19-update-that-boosts-antibodies-4-fold-in-high-risk-adults

Pfizer and BioNTech's LP.8.1 COVID-19 vaccine boosts antibodies 4-fold in high-risk adults, with no new safety concerns rep...

 biontech-bristol-myers-squibb-show-tumor-shrinkage-in-lung-cancer-immunotherapy

BioNTech and Bristol Myers report strong interim results for pumitamig plus chemo in lung cancer, showing high response rates.

Core News & Articles

PD-L1xVEGF-A bispecific antibody pumitamig (BNT327/BMS986545) plus chemotherapy continues to show encouraging antitumor activit...

 hc-wainwright--co-reiterates-buy-on-biontech-maintains-136-price-target

HC Wainwright & Co. analyst Robert Burns reiterates BioNTech (NASDAQ:BNTX) with a Buy and maintains $136 price target.

Core News & Articles

Phase 3 clinical trial cohort of adults 65+ and 18-64 with at least one underlying risk condition shows at least a 4-fold incre...

 biontech-advances-on-positive-phase-3-breast-cancer-drug-data

BioNTech and DualityBio reported Phase 3 success for trastuzumab pamirtecan in HER2 breast cancer, setting stage for regulatory...

 biontechs-trastuzumab-pamirtecan-investigational-next-generation-antibody-drug-conjugate-targeting-her-2-met-its-primary-endpoint-of-progression-free-survival-in-interim-analysis-of-a-phase-3-trial-conducted-in-china

 BioNTech SE (NASDAQ:BNTX) and Duality Biologics (Suzhou) Co., Ltd. ("DualityBio") today announced that the pivotal Pha...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION